Byetta/Januvia Pancreatic Cancer

Nonprofit consumer advocacy group Public Citizen has submitted a petition to the U.S. Food and Drug Administration, calling for a diabetes drug to be banned in light of studies linking the it to pancreatic and thyroid cancer.

According to a story about the issue in the journal Nature, a patient stands just a 1.8% chance of surviving for longer than five years once pancreatic cancer spreads.

The FDA approved Victoza, made by Novo Nordisk of Denmark, in 2010. The drug mimics the ...

A story in the New York Times concerns efforts by federal regulators to develop a stronger label for the diabetes drug Byetta, manufactured by Eli Lilly, following more reports of deadly pancreatitis.

The U.S. Food and Drug Administration reported an additional six cases of pancreatitis. Two of the patients died and four were recovering.

An earlier FDA alert cited about 30 reports of Byetta patients developing a dangerous form of pancreatitis, which ...

A report on the blog FiercePharma says the European Medicines Agency – which evaluates medical products for the European Union – has approved an expanded use of the drug Byetta for type 2 diabetes patients.

Byetta is now approved for use with or without other medications such as metformin and Actos, to help adults who have been unable to get their blood sugars under control.

The decision was expected after an advisory ...

A study suggests that two diabetes drugs – Januvia and Byetta – may raise the risk of pancreatitis and pancreatic cancer, according to a story in USA Today. The study found that Byetta may also carry an increased risk of thyroid cancer.

Lopez McHugh is reviewing cases involving pancreatic cancer with Januvia and Byetta. If you or a loved one received this diagnosis while on either of these drugs, call or ...